Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTMX |
---|---|---|
09:32 ET | 7357 | 1.3 |
09:34 ET | 100 | 1.29 |
09:36 ET | 800 | 1.28 |
09:38 ET | 2417 | 1.2741 |
09:39 ET | 4600 | 1.27 |
09:41 ET | 300 | 1.275 |
09:43 ET | 800 | 1.27 |
09:45 ET | 3400 | 1.2701 |
09:48 ET | 2300 | 1.275 |
09:50 ET | 2558 | 1.275 |
09:52 ET | 2505 | 1.2711 |
09:54 ET | 2183 | 1.275 |
09:56 ET | 1598 | 1.275 |
09:57 ET | 2201 | 1.2711 |
09:59 ET | 1298 | 1.27 |
10:01 ET | 600 | 1.275 |
10:03 ET | 300 | 1.27 |
10:06 ET | 1498 | 1.275 |
10:08 ET | 4437 | 1.285 |
10:10 ET | 1300 | 1.28 |
10:12 ET | 100 | 1.27 |
10:14 ET | 200 | 1.27 |
10:15 ET | 200 | 1.275 |
10:17 ET | 500 | 1.275 |
10:19 ET | 100 | 1.275 |
10:24 ET | 100 | 1.275 |
10:26 ET | 2760 | 1.28 |
10:28 ET | 1398 | 1.28 |
10:30 ET | 317 | 1.275 |
10:32 ET | 700 | 1.28 |
10:33 ET | 1830 | 1.2712 |
10:35 ET | 3425 | 1.285 |
10:37 ET | 400 | 1.285 |
10:39 ET | 1200 | 1.28 |
10:42 ET | 400 | 1.285 |
10:44 ET | 400 | 1.29 |
10:46 ET | 200 | 1.29 |
10:48 ET | 500 | 1.29 |
10:50 ET | 400 | 1.285 |
10:51 ET | 19647 | 1.29 |
10:53 ET | 5318 | 1.28 |
10:55 ET | 2170 | 1.29 |
10:57 ET | 300 | 1.29 |
11:00 ET | 400 | 1.29 |
11:02 ET | 200 | 1.285 |
11:04 ET | 200 | 1.285 |
11:06 ET | 200 | 1.285 |
11:08 ET | 500 | 1.2864 |
11:09 ET | 1100 | 1.28 |
11:11 ET | 200 | 1.285 |
11:13 ET | 1300 | 1.285 |
11:15 ET | 200 | 1.285 |
11:18 ET | 300 | 1.28 |
11:20 ET | 200 | 1.285 |
11:22 ET | 100 | 1.28 |
11:26 ET | 400 | 1.28 |
11:27 ET | 500 | 1.2801 |
11:29 ET | 100 | 1.285 |
11:31 ET | 100 | 1.28 |
11:33 ET | 200 | 1.285 |
11:36 ET | 100 | 1.28 |
11:38 ET | 400 | 1.28 |
11:40 ET | 600 | 1.28 |
11:44 ET | 200 | 1.285 |
11:45 ET | 300 | 1.285 |
11:47 ET | 100 | 1.285 |
11:49 ET | 4662 | 1.29 |
11:51 ET | 6255 | 1.3 |
11:54 ET | 13546 | 1.29 |
11:56 ET | 1611 | 1.3 |
11:58 ET | 300 | 1.295 |
12:00 ET | 600 | 1.29 |
12:02 ET | 1400 | 1.295 |
12:03 ET | 300 | 1.29 |
12:05 ET | 300 | 1.29 |
12:07 ET | 300 | 1.29 |
12:09 ET | 1907 | 1.29 |
12:12 ET | 500 | 1.29 |
12:14 ET | 6169 | 1.28 |
12:16 ET | 500 | 1.28 |
12:18 ET | 600 | 1.28 |
12:20 ET | 400 | 1.285 |
12:21 ET | 400 | 1.28 |
12:23 ET | 400 | 1.28 |
12:25 ET | 200 | 1.28 |
12:27 ET | 500 | 1.28 |
12:30 ET | 200 | 1.28 |
12:32 ET | 1489 | 1.285 |
12:34 ET | 7644 | 1.28 |
12:36 ET | 600 | 1.27 |
12:38 ET | 600 | 1.275 |
12:39 ET | 200 | 1.27 |
12:41 ET | 4685 | 1.275 |
12:43 ET | 500 | 1.275 |
12:45 ET | 1000 | 1.27 |
12:48 ET | 3630 | 1.28 |
12:50 ET | 500 | 1.27 |
12:52 ET | 500 | 1.275 |
12:54 ET | 3227 | 1.28 |
12:56 ET | 600 | 1.27 |
12:57 ET | 2743 | 1.275 |
12:59 ET | 200 | 1.275 |
01:01 ET | 500 | 1.27 |
01:03 ET | 3161 | 1.275 |
01:06 ET | 300 | 1.275 |
01:08 ET | 500 | 1.27 |
01:10 ET | 3949 | 1.27 |
01:12 ET | 500 | 1.27 |
01:14 ET | 194 | 1.27 |
01:15 ET | 2642 | 1.28 |
01:17 ET | 800 | 1.27 |
01:19 ET | 500 | 1.27 |
01:21 ET | 400 | 1.27 |
01:24 ET | 2512 | 1.28 |
01:26 ET | 500 | 1.275 |
01:28 ET | 300 | 1.27 |
01:30 ET | 400 | 1.28 |
01:32 ET | 2921 | 1.275 |
01:33 ET | 400 | 1.27 |
01:35 ET | 300 | 1.27 |
01:37 ET | 400 | 1.27 |
01:39 ET | 2837 | 1.27 |
01:42 ET | 2500 | 1.27 |
01:44 ET | 200 | 1.27 |
01:46 ET | 300 | 1.27 |
01:48 ET | 2935 | 1.275 |
01:50 ET | 500 | 1.27 |
01:51 ET | 1469 | 1.27 |
01:53 ET | 5179 | 1.28 |
01:55 ET | 300 | 1.275 |
01:57 ET | 900 | 1.28 |
02:00 ET | 900 | 1.27 |
02:02 ET | 2636 | 1.28 |
02:04 ET | 600 | 1.27 |
02:06 ET | 6920 | 1.28 |
02:08 ET | 900 | 1.27 |
02:09 ET | 400 | 1.275 |
02:11 ET | 600 | 1.27 |
02:13 ET | 400 | 1.27 |
02:15 ET | 2679 | 1.28 |
02:18 ET | 400 | 1.275 |
02:20 ET | 300 | 1.275 |
02:22 ET | 900 | 1.275 |
02:24 ET | 682 | 1.275 |
02:26 ET | 3538 | 1.275 |
02:27 ET | 400 | 1.27 |
02:29 ET | 600 | 1.275 |
02:31 ET | 2578 | 1.27 |
02:33 ET | 1678 | 1.275 |
02:36 ET | 500 | 1.27 |
02:38 ET | 700 | 1.27 |
02:40 ET | 2643 | 1.27 |
02:42 ET | 500 | 1.27 |
02:44 ET | 400 | 1.27 |
02:45 ET | 11818 | 1.275 |
02:47 ET | 541 | 1.275 |
02:49 ET | 300 | 1.27 |
02:51 ET | 558 | 1.275 |
02:54 ET | 3936 | 1.27 |
02:56 ET | 742 | 1.27 |
02:58 ET | 400 | 1.27 |
03:00 ET | 900 | 1.275 |
03:02 ET | 3138 | 1.275 |
03:03 ET | 700 | 1.275 |
03:05 ET | 1000 | 1.27 |
03:07 ET | 1300 | 1.275 |
03:09 ET | 5509 | 1.275 |
03:12 ET | 1500 | 1.28 |
03:14 ET | 400 | 1.28 |
03:16 ET | 2619 | 1.28 |
03:18 ET | 2566 | 1.275 |
03:20 ET | 1200 | 1.27 |
03:21 ET | 21353 | 1.29 |
03:23 ET | 2602 | 1.28 |
03:25 ET | 700 | 1.285 |
03:27 ET | 1600 | 1.285 |
03:30 ET | 3748 | 1.285 |
03:32 ET | 2618 | 1.28 |
03:34 ET | 2639 | 1.28 |
03:36 ET | 2941 | 1.285 |
03:38 ET | 7559 | 1.28 |
03:39 ET | 715 | 1.285 |
03:41 ET | 4514 | 1.28 |
03:43 ET | 792 | 1.28 |
03:45 ET | 9508 | 1.3 |
03:48 ET | 1800 | 1.29 |
03:50 ET | 500 | 1.295 |
03:52 ET | 4164 | 1.295 |
03:54 ET | 800 | 1.295 |
03:56 ET | 1540 | 1.29 |
03:57 ET | 4546 | 1.29 |
03:59 ET | 79696 | 1.29 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CytomX Therapeutics Inc | 100.5M | 6.5x | --- |
Spero Therapeutics Inc | 70.7M | 3.1x | --- |
2Seventy Bio Inc | 207.2M | -0.9x | --- |
Rigel Pharmaceuticals Inc | 136.6M | -6.9x | --- |
G1 Therapeutics Inc | 131.2M | -4.1x | --- |
Seres Therapeutics Inc | 123.0M | -1.3x | --- |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $100.5M |
---|---|
Revenue (TTM) | $119.2M |
Shares Outstanding | 77.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.06 |
EPS | $0.20 |
Book Value | $-0.70 |
P/E Ratio | 6.5x |
Price/Sales (TTM) | 0.8 |
Price/Cash Flow (TTM) | 5.4x |
Operating Margin | 9.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.